Singapore markets closed
Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,896.54 +1,705.00 (+2.58%) CMC Crypto 200
1,373.18 +42.57 (+3.20%)
Wilmar International Limited (F34.SI)
SES - SES Delayed price. Currency in SGD
Add to watchlist
At close: 05:13PM SGT
| Previous close | 3.1000 |
| Open | 3.1200 |
| Bid | 3.0900 x 0 |
| Ask | 3.1000 x 0 |
| Day's range | 3.0900 - 3.1300 |
| 52-week range | 3.0700 - 3.9300 |
| Volume | |
| Avg. volume | 5,485,374 |
| Market cap | 19.352B |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | 9.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.17 (5.48%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.
© 2024 Yahoo. All rights reserved.